Advanced melanoma is melanoma that has spread beyond its original site on the skin, either into nearby lymph nodes or to distant organs like the lungs, liver, brain, or bones. It encompasses Stage III and Stage IV disease. The five-year survival rate ranges from 76% for regional spread down to 34% for distant metastasis, though newer treatments approved in the last decade have dramatically improved these numbers and continue to push them higher.
How Melanoma Becomes “Advanced”
Melanoma starts in the pigment-producing cells of the skin. In its early stages, it stays within or just below the surface. It becomes advanced when cells break away from the original tumor and travel to other parts of the body. This happens through two main routes: the lymphatic system and the bloodstream.
Research from the National Cancer Institute has clarified why melanoma so often spreads to lymph nodes first. Melanoma cells traveling through lymph fluid absorb a fatty acid called oleic acid, which gets built into their outer membranes and shields them from a type of cell death triggered by oxidative stress. Cells in the bloodstream don’t get that protection, making the lymph node route a safer path for the cancer. Once melanoma cells survive and adapt in the lymph nodes, they become hardier and better equipped to enter the bloodstream and reach distant organs.
Stage III vs. Stage IV
Stage III melanoma means the cancer has reached nearby lymph nodes or developed satellite tumors in the skin between the original melanoma and the nearest lymph nodes. These satellite deposits and “in-transit” metastases (small clusters of cancer cells traveling through the lymphatic channels near the primary site) are all grouped together for staging purposes. The number of affected lymph nodes and whether they were found through microscopic examination or were large enough to detect physically both factor into how Stage III is further subdivided.
Stage IV means the cancer has traveled to distant parts of the body. The most common sites include the lungs, liver, brain, bones, and small intestine. Staging at this point depends on where the cancer has landed and whether a blood marker called LDH is elevated, which can signal more aggressive disease. Brain metastases carry their own specific designation because they present unique treatment challenges and tend to affect prognosis differently than spread to other organs.
Symptoms Beyond the Skin
Advanced melanoma often causes symptoms that seem unrelated to a skin problem, and the specific symptoms depend on where the cancer has spread.
- Lymph nodes: Hard or swollen lumps in the neck, armpit, or groin. Swollen nodes can block lymph fluid drainage, causing swelling in a nearby arm, leg, or the face. Neck involvement can make swallowing difficult.
- Lungs: A persistent cough, shortness of breath, coughing up blood, or fluid buildup between the lung and chest wall.
- Brain: Severe headaches (often with nausea), memory problems, personality changes, confusion, seizures, or weakness on one side of the body.
- Liver: Pain or discomfort on the right side of the abdomen, poor appetite, weight loss, yellowing of the skin, itching, or a swollen abdomen from fluid accumulation.
- Bones: Deep, continuous gnawing pain, backache that doesn’t improve with rest, and bones that fracture more easily. Cancer in the spinal bones can press on the spinal cord, potentially causing leg weakness, numbness, or loss of bladder and bowel control.
- Small intestine: Abdominal pain, nausea, weight loss, and anemia.
General symptoms like unexplained weight loss, persistent fatigue, and feeling generally unwell are also common, regardless of where the cancer has spread.
Genetic Testing and Why It Matters
One of the first things that happens after an advanced melanoma diagnosis is genetic testing of the tumor itself. Roughly 35% to 50% of all melanomas carry a mutation in a gene called BRAF, which acts like a stuck accelerator pedal, telling cancer cells to keep dividing. The most common version of this mutation, called V600E, accounts for 70% to 80% of BRAF-mutated cases. Another variant, V600K, makes up 10% to 20%. Rarer BRAF mutations occur in 3% to 14% of cases.
Knowing the mutation status directly shapes treatment. Patients with BRAF mutations have access to targeted therapies that block that specific growth signal. Patients without these mutations rely on different treatment strategies, primarily immunotherapy. This is why tumor profiling has become a standard, non-negotiable step in managing advanced melanoma.
How Advanced Melanoma Is Treated
Treatment for advanced melanoma has transformed over the past decade. Where chemotherapy was once the only systemic option, the FDA has now approved more than two dozen drugs for melanoma, most of them falling into two main categories.
Immunotherapy
Immunotherapy drugs work by removing the brakes that cancer puts on your immune system. The most widely used are checkpoint inhibitors, which block proteins that melanoma uses to hide from immune cells. These drugs are given by IV infusion, typically every few weeks. For many patients, immunotherapy is the first treatment offered because it can produce durable responses, meaning the cancer stays controlled for years in some cases. Combination immunotherapy, using two checkpoint inhibitors together, produces higher response rates but also more side effects.
Targeted Therapy
For patients whose tumors carry a BRAF mutation, targeted therapy pairs a drug that blocks the BRAF protein with a second drug that blocks a related growth signal downstream. These are oral medications taken daily. They often shrink tumors quickly, which makes them especially useful when the cancer is causing dangerous symptoms that need a fast response. The trade-off is that resistance tends to develop over time, and many patients eventually need to switch to or add immunotherapy.
Cell-Based Therapy
In February 2024, the FDA approved a new kind of treatment called tumor-infiltrating lymphocyte (TIL) therapy for patients whose melanoma has progressed after previous treatments. The approach involves surgically removing a piece of the patient’s tumor, isolating the immune cells found within it, growing billions of copies of those cells in a lab, and then infusing them back into the patient. In the clinical trial that led to approval, 31.5% of patients saw their tumors shrink meaningfully, and the duration of those responses was long enough that researchers hadn’t yet identified a median endpoint at the time of publication. This treatment is intensive, requiring a hospital stay and preparatory chemotherapy to make room for the new immune cells, but it offers a meaningful option for patients who have run out of other choices.
What Survival Rates Actually Mean
The current five-year relative survival rate for melanoma that has spread to nearby lymph nodes is 76%. For melanoma that has reached distant organs, it drops to 34%. These numbers come from the SEER database and reflect patients diagnosed between 2016 and 2022.
Context matters here. These statistics include patients diagnosed years ago, some before the newest treatments were available. For someone starting treatment today with current immunotherapy and targeted therapy options, outcomes are likely better than what these historical numbers suggest. Individual prognosis also varies enormously based on factors like how many organs are involved, whether the brain is affected, the tumor’s genetic profile, and how well the cancer responds to the first round of treatment.
Palliative Care as Part of Treatment
Palliative care is not the same as hospice or end-of-life care. It’s a specialized medical service focused on managing symptoms and improving quality of life alongside active cancer treatment. For advanced melanoma patients, that can mean help with pain, appetite loss, insomnia, or the emotional weight of the diagnosis. Research has shown that cancer patients who receive palliative care early report better quality of life, fewer symptoms of depression, and in some cases, actually live longer than patients who don’t receive it.
Palliative care teams typically include not just doctors and nurses, but social workers and other specialists who can help with the practical and emotional challenges that come with a serious diagnosis. Family members and caregivers can access these services too.